MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas-Reference-Cited by-同舟云学术

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas

Published:2018 Issue:7 Volume:58 Page:290-295
ISSN:0470-8105
Container-title:Neurologia medico-chirurgica
language:en
Short-container-title:Neurol. Med. Chir.(Tokyo)

Author:

ABE Hideaki¹,NATSUMEDA Manabu¹,KANEMARU Yu¹,WATANABE Jun¹,TSUKAMOTO Yoshihiro¹,OKADA Masayasu¹,YOSHIMURA Junichi¹,OISHI Makoto¹,FUJII Yukihiko¹

Affiliation:

1. Department of Neurosurgery, Brain Research Institute, Niigata University

Publisher

Japan Neurosurgical Society

Subject

Clinical Neurology,Surgery

Link

https://www.jstage.jst.go.jp/article/nmc/58/7/58_ra.2018-0044/_pdf

Reference49 articles.

1. 1) Hargrave D, Bartels U, Bouffet E: Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7: 241–248, 2006

2. 2) Buczkowicz P, Bartels U, Bouffet E, et al.: Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol 128: 573–581, 2014

3. 3) Esquenazi Y, Moussazadeh N, Link TW, et al.: Thalamic glioblastoma: clinical presentation, management strategies, and outcomes. Neurosurgery 2017

4. 4) Saito R, Kumabe T, Kanamori M, Sonoda Y, Tominaga T: Distant recurrences limit the survival of patients with thalamic high-grade gliomas after successful resection. Neurosurg Rev 40: 469–477, 2017`

5. 5) Kelly PJ: Stereotactic biopsy and resection of thalamic astrocytomas. Neurosurgery 25: 185–195, 1989

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tricarboxylic Acid Cycle Relationships with Non-Metabolic Processes: A Short Story with DNA Repair and Its Consequences on Cancer Therapy Resistance;International Journal of Molecular Sciences;2024-08-21

2. Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies;Cancer Letters;2024-05

3. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma;Journal of Clinical Oncology;2024-05-01

4. Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma;Neuro-Oncology;2024-04-01

5. ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma;Neuro-Oncology;2024-03-06